Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: Clinical outcomes and effect on T-regulatory cells

J. Pascual, D. Bloom, J. Torrealba, R. Brahmbhatt, Z. Chang, H. W. Sollinger, S. J. Knechtle

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

To address the results of calcineurin inhibitor (CNI) withdrawal after alemtuzumab induction relative to CNI continuation, we performed a pilot randomized clinical trial in renal allograft recipients on CNI, a mycophenolic acid derivative and steroids after the first 2 months posttransplantation. Forty patients were randomized to taper off CNI or to maintain it, and followed for at least 1 year. Four patients in the withdrawal group were treated for acute rejection while no patient received antirejection treatment in the control group. Two control patients withdrew CNI due to nephrotoxicity. Estimated GFR was similar in both groups after 1 year. Flow cytometry of CD4 +CD25+CTLA-4+FoxP3+ regulatory T cells (Treg) demonstrated a significant increase in Treg percentages in the peripheral blood of alemtuzumab-treated patients on CNI early postransplant. Furthermore, the increased Treg percentages in the withdrawal cohort were unchanged at month 6 postenrollment, whereas they decreased significantly in those patients maintained on CNI. Patients withdrawn from CNI after alemtuzumab trend toward a higher rejection rate, but most patients can be weaned from a CNI using this regimen. With the exception of maintaining increased Treg levels, the benefits are not appreciable in this short follow-up, and a larger randomized trial is justified.

Original languageEnglish (US)
Pages (from-to)1529-1536
Number of pages8
JournalAmerican Journal of Transplantation
Volume8
Issue number7
DOIs
StatePublished - Jul 2008

Fingerprint

Regulatory T-Lymphocytes
Kidney Transplantation
Mycophenolic Acid
Calcineurin Inhibitors
alemtuzumab
Allografts
Flow Cytometry
Randomized Controlled Trials
Steroids
Kidney
Control Groups

Keywords

  • Alemtuzumab
  • Calcineurin inhibitor agents
  • Calculated glomerular filtration rate
  • Campath-1H
  • CD4+CD25+ T cells
  • Chronic nephrotoxicity
  • Clinical kidney transplantation
  • CNI nephrotoxicity
  • Foxp3
  • Immunosuppression withdrawal T-regulatory cells

ASJC Scopus subject areas

  • Immunology

Cite this

Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab : Clinical outcomes and effect on T-regulatory cells. / Pascual, J.; Bloom, D.; Torrealba, J.; Brahmbhatt, R.; Chang, Z.; Sollinger, H. W.; Knechtle, S. J.

In: American Journal of Transplantation, Vol. 8, No. 7, 07.2008, p. 1529-1536.

Research output: Contribution to journalArticle

Pascual, J. ; Bloom, D. ; Torrealba, J. ; Brahmbhatt, R. ; Chang, Z. ; Sollinger, H. W. ; Knechtle, S. J. / Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab : Clinical outcomes and effect on T-regulatory cells. In: American Journal of Transplantation. 2008 ; Vol. 8, No. 7. pp. 1529-1536.
@article{357386799e514bb6b9f9aeeaf715325b,
title = "Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: Clinical outcomes and effect on T-regulatory cells",
abstract = "To address the results of calcineurin inhibitor (CNI) withdrawal after alemtuzumab induction relative to CNI continuation, we performed a pilot randomized clinical trial in renal allograft recipients on CNI, a mycophenolic acid derivative and steroids after the first 2 months posttransplantation. Forty patients were randomized to taper off CNI or to maintain it, and followed for at least 1 year. Four patients in the withdrawal group were treated for acute rejection while no patient received antirejection treatment in the control group. Two control patients withdrew CNI due to nephrotoxicity. Estimated GFR was similar in both groups after 1 year. Flow cytometry of CD4 +CD25+CTLA-4+FoxP3+ regulatory T cells (Treg) demonstrated a significant increase in Treg percentages in the peripheral blood of alemtuzumab-treated patients on CNI early postransplant. Furthermore, the increased Treg percentages in the withdrawal cohort were unchanged at month 6 postenrollment, whereas they decreased significantly in those patients maintained on CNI. Patients withdrawn from CNI after alemtuzumab trend toward a higher rejection rate, but most patients can be weaned from a CNI using this regimen. With the exception of maintaining increased Treg levels, the benefits are not appreciable in this short follow-up, and a larger randomized trial is justified.",
keywords = "Alemtuzumab, Calcineurin inhibitor agents, Calculated glomerular filtration rate, Campath-1H, CD4+CD25+ T cells, Chronic nephrotoxicity, Clinical kidney transplantation, CNI nephrotoxicity, Foxp3, Immunosuppression withdrawal T-regulatory cells",
author = "J. Pascual and D. Bloom and J. Torrealba and R. Brahmbhatt and Z. Chang and Sollinger, {H. W.} and Knechtle, {S. J.}",
year = "2008",
month = "7",
doi = "10.1111/j.1600-6143.2008.02260.x",
language = "English (US)",
volume = "8",
pages = "1529--1536",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab

T2 - Clinical outcomes and effect on T-regulatory cells

AU - Pascual, J.

AU - Bloom, D.

AU - Torrealba, J.

AU - Brahmbhatt, R.

AU - Chang, Z.

AU - Sollinger, H. W.

AU - Knechtle, S. J.

PY - 2008/7

Y1 - 2008/7

N2 - To address the results of calcineurin inhibitor (CNI) withdrawal after alemtuzumab induction relative to CNI continuation, we performed a pilot randomized clinical trial in renal allograft recipients on CNI, a mycophenolic acid derivative and steroids after the first 2 months posttransplantation. Forty patients were randomized to taper off CNI or to maintain it, and followed for at least 1 year. Four patients in the withdrawal group were treated for acute rejection while no patient received antirejection treatment in the control group. Two control patients withdrew CNI due to nephrotoxicity. Estimated GFR was similar in both groups after 1 year. Flow cytometry of CD4 +CD25+CTLA-4+FoxP3+ regulatory T cells (Treg) demonstrated a significant increase in Treg percentages in the peripheral blood of alemtuzumab-treated patients on CNI early postransplant. Furthermore, the increased Treg percentages in the withdrawal cohort were unchanged at month 6 postenrollment, whereas they decreased significantly in those patients maintained on CNI. Patients withdrawn from CNI after alemtuzumab trend toward a higher rejection rate, but most patients can be weaned from a CNI using this regimen. With the exception of maintaining increased Treg levels, the benefits are not appreciable in this short follow-up, and a larger randomized trial is justified.

AB - To address the results of calcineurin inhibitor (CNI) withdrawal after alemtuzumab induction relative to CNI continuation, we performed a pilot randomized clinical trial in renal allograft recipients on CNI, a mycophenolic acid derivative and steroids after the first 2 months posttransplantation. Forty patients were randomized to taper off CNI or to maintain it, and followed for at least 1 year. Four patients in the withdrawal group were treated for acute rejection while no patient received antirejection treatment in the control group. Two control patients withdrew CNI due to nephrotoxicity. Estimated GFR was similar in both groups after 1 year. Flow cytometry of CD4 +CD25+CTLA-4+FoxP3+ regulatory T cells (Treg) demonstrated a significant increase in Treg percentages in the peripheral blood of alemtuzumab-treated patients on CNI early postransplant. Furthermore, the increased Treg percentages in the withdrawal cohort were unchanged at month 6 postenrollment, whereas they decreased significantly in those patients maintained on CNI. Patients withdrawn from CNI after alemtuzumab trend toward a higher rejection rate, but most patients can be weaned from a CNI using this regimen. With the exception of maintaining increased Treg levels, the benefits are not appreciable in this short follow-up, and a larger randomized trial is justified.

KW - Alemtuzumab

KW - Calcineurin inhibitor agents

KW - Calculated glomerular filtration rate

KW - Campath-1H

KW - CD4+CD25+ T cells

KW - Chronic nephrotoxicity

KW - Clinical kidney transplantation

KW - CNI nephrotoxicity

KW - Foxp3

KW - Immunosuppression withdrawal T-regulatory cells

UR - http://www.scopus.com/inward/record.url?scp=47249132479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249132479&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2008.02260.x

DO - 10.1111/j.1600-6143.2008.02260.x

M3 - Article

C2 - 18510645

AN - SCOPUS:47249132479

VL - 8

SP - 1529

EP - 1536

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 7

ER -